查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858230

α1-抗胰蛋白酶缺乏症治療市場按治療方法、通路、給藥方式、最終用戶和患者年齡層分類 - 全球預測（2025-2032 年）

Alpha 1 Antitrypsin Deficiency Treatment Market by Therapy Class, Distribution Channel, Delivery Mode, End User, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，α-1 抗胰蛋白酶缺乏症治療市場將成長至 67.9 億美元，複合年成長率為 9.62%。

關鍵市場統計數據
基準年 2024 32.6億美元
預計年份：2025年 35.7億美元
預測年份 2032 67.9億美元
複合年成長率 (%) 9.62%

本書清晰而有力地概述了α1-抗胰蛋白酶缺乏症治療模式演變過程中的科學進展和患者就醫挑戰。

α1-抗胰蛋白酶缺乏症是一種具有重要臨床意義的遺傳性疾病，會顯著影響肺功能和肝功能等。這促使治療格局不斷發展，將成熟的生物製藥與新一代基因療法結合。過去十年，臨床實踐主要依賴替代療法和血漿衍生療法來穩定以肺部受累為主的患者病情，而轉化研究的蓬勃發展則推動了基因療法進入臨床應用。因此，研發、生產和醫療服務等各環節的相關人員正在重新調整工作重點，以平衡長期臨床預期與短期可近性挑戰。

如本執行摘要所述，該領域的特點是治療方式和給藥模式的多樣性。雖然傳統的增強療法和血漿輸注仍然是許多患者的核心治療選擇，但以腺結合病毒和慢病毒載體為特色的基因療法平台正在發展成為潛在的根治性方案。通路正從醫院藥房轉向線上和零售管道，給藥方式也日益多樣化，包括吸入和靜脈注射，這些都在重塑著患者獲得治療的方式。患者群體的多樣性，包括成人、老年患者和兒童，進一步增加了臨床路徑和報銷方式的複雜性。綜上所述，這些趨勢要求在研究、供應鏈和商業性執行方面製定協調一致的策略，以將科學進步轉化為實際的患者獲益。

科學進步、劑量創新和分銷管道的改變如何重塑 AATD 治療的臨床開發和商業性進程

α1-抗胰蛋白酶缺乏症的治療格局正因科學、監管和商業性的重大轉折點而發生變革，這些轉折點共同重新定義了研發重點。載體生物學和基因編輯平台的突破性進展正在加速轉化研究，並增加探索基於腺相關病毒（AAV）和慢病毒載體療法的早期臨床試驗的頻率。同時，載體生產、純化和衣殼工程技術的進步正在縮小實驗室可行性與可擴展臨床供應之間的差距，這正在影響關鍵性臨床試驗計畫的規劃。

同時，給藥方式的創新正在重塑臨床設計和病患體驗。吸入給藥策略因其直接肺部給藥以控制肺部疾病而日益受到重視，而靜脈注射途徑則在全身暴露和基因遞送方面不斷最佳化。通路也在不斷調整，醫院藥房在複雜輸液和特殊操作中仍然發揮著核心作用，而線上藥房和零售藥房則在拓展業務，以支持維持治療和慢性病護理的物流。這些技術和物流方面的變革與支付方的期望和監管路徑相互交織，促使研發人員投入資源，以產生可靠的真實世界證據並監測長期安全性。因此，生物技術創新者、合約開發組織和專業醫療保健網路之間的合作對於快速將候選藥物從研究階段推進到臨床實踐至關重要。

2025年美國關稅政策變化對生物製藥供應鏈、採購趨勢和病患取得途徑的策略影響

貿易和關稅政策的變化對醫藥和生物製藥生態系統產生了實際且迅速的影響。美國於2025年宣布的關稅措施的累積影響，將需要供應鏈、採購和定價管道進行策略性調整。影響進口原料和生產組件的關稅可能會增加血漿衍生產品和生物載體生產的直接生產成本，這些產品通常需要從國外購買專用試劑和設備。這些成本壓力可能會波及契約製造關係，迫使各方重新談判供應條款，並將生產規模策略性地重新分配到國內工廠。

除了直接的成本影響外，關稅還會降低庫存靈活性，延長關鍵材料的前置作業時間，從而增加供應鏈計劃的複雜性，並提高依賴穩定血漿供應或按時生產載體的專案的營運風險。醫院藥局和專科診所的採購團隊可能會面臨利潤壓力，這可能導致採購模式的改變和合約結構的重新評估。為此，發起機構可以透過加快關鍵生產流程的本地化、尋求長期供應協議或尋找合格的替代供應商來降低風險。重點，監管方面的考慮和支付方的談判將影響增量成本最終如何在支付方、醫療服務提供方和患者之間分配，因此，包括證據收集和定價模型在內的跨職能緩解策略對於確保患者獲得治療至關重要。

深入的市場細分洞察，解釋了治療層級、通路、給藥方式、最終使用環境和患者人口統計特徵如何決定策略重點和營運權衡。

對α1-抗胰蛋白酶缺乏症治療領域的細分分析突顯了相關人員必須關注的不同商業性和臨床載體，以最佳化開發和應用。就治療層級而言，替代療法和血漿輸注仍然是許多患者目前治療的基礎，營運重點在於血漿採集網路、低溫運輸物流和輸注基礎設施。基因治療具有獨特的風險回報特徵。在此類別中，腺相關病毒（AAV）載體方法因其靶向肝臟和肺部的體內基因遞送優勢而備受青睞，而慢病毒載體策略通常用於體外造血模型或特定的全身遞送靶點。每種載體類型都涉及獨特的生產、免疫抗原性和監管方面的考量，這些因素會影響臨床試驗設計和長期安全性監測。

通路的變化趨勢對患者的用藥可及性和依從性有顯著影響。雖然醫院藥局在複雜、高度規範的療法和基因療法的初始給藥方面仍然至關重要，但線上藥局正逐漸成為慢性病護理和宅配計畫的便捷途徑。零售藥局提供社區層面的用藥服務，並通常支持維持治療的連續性。給藥方式的選擇進一步加劇了患者體驗的差異：吸入療法能夠實現標靶肺部沉積，並為門診患者帶來更多便利；而靜脈注射則有助於在臨床環境中實現全身暴露和劑量控制。最終使用者的差異也十分重要：居家照護模式允許病患在醫療機構外進行慢性輸注；醫院是急診和複雜手術的中心；而專科診所則集中了基因治療給藥和長期監測方面的專業知識。最後，患者年齡層的差異也造成了臨床差異，影響治療方案的選擇、給藥策略和安全性監測。兒科患者需要兒科專用製劑和發展階段相適應的安全性數據，而成人通常是最大的治療族群。老年患者面臨合併症和多重用藥等問題，這些問題會影響藥物的耐受性和治療效果。

區域間法規環境、臨床基礎設施和供應鏈能力的差異將如何影響全球市場的發展路徑和病患獲取途徑

區域趨勢將對α1-抗胰蛋白酶缺乏症計畫的臨床開發、報銷策略和供應鏈韌性產生重大影響。在美洲，重點研究活動、完善的臨床試驗基礎設施和成熟的血漿採集系統共同為先進療法的開發創造了有利環境。監管途徑仍然是核心考慮因素，監管機構要求提供可靠的安全性數據和長期追蹤數據，以確定試驗終點和核准後義務。該地區的商業相關人員還必須應對支付方的期望和複雜的醫院採購流程，以確保治療方法的廣泛應用。

歐洲、中東和非洲地區（EMEA）的監管和准入環境複雜多樣，既有集中式框架，也有國家層面的框架。雖然一些歐洲市場提供強力的孤兒藥誘因和加速核准機制，但報銷標準和衛生技術評估要求的差異可能導致各國在藥物可近性方面有顯著差異。在中東和非洲部分地區，血漿基礎設施有限且缺乏專業的醫療網路，使得先進療法的引入更加複雜，凸顯了進行有針對性能力建設工作的重要性。

亞太地區的特點是臨床研究活動快速擴張、本地生產能力不斷提升，以及監管協調日益加強，旨在縮短臨床開發週期。該地區多個國家正在投資生物製造和載體生產能力，這有望支持區域供應多元化。然而，病患可及性和定價趨勢因市場而異，因此需要製定反映當地支付體系、分銷生態系統和醫療實踐模式的複雜商業化策略。在所有地區，管理跨境供應鏈、海關風險和物流應急措施對於確保產品供應穩定和患者照護的連續性仍然至關重要。

深入了解產業相關人員之間的策略聯盟、製造投資和實證項目如何加速臨床應用和商業化進程。

企業和生態系統層面的努力正在影響創新型AATD治療方法從概念到臨床，最終走向常規實踐的進程。包括小型生物技術創新者、成熟的血漿療法公司、合約研發生產機構和專科藥房網路在內的多元化參與者，在藥物發現、載體生產和患者支持方面提供互補的能力。隨著研發人員尋求將科學專長與大規模生產能力和成熟的分銷網路相結合，戰略合作和許可授權變得越來越普遍。

為了因應基因治療和血漿衍生產品營運的複雜性，商業機構正優先投資於載體生產、低溫運輸物流和病患支援服務的產能。能夠證明其生產產量穩定且品質系統符合規範的契約製造製造商，是尋求降低關鍵專案風險的申辦方的策略夥伴。同時，專科藥房和家庭輸液服務提供者正在加強其臨床支援和監測項目，以最佳化患者的依從性和安全性。在商業層面，各公司也致力於制定循證策略，使臨床結果與支付方的要求相符，強調真實世界療效、生活品質指標和長期安全性數據，以推動醫保覆蓋和報銷方面的討論。總而言之，這些企業層面的選擇凸顯了整合式、跨職能模式的轉變，這種模式將卓越的臨床水準與商業性現實相結合。

為贊助商和合作夥伴提供切實可行的優先策略步驟，以加強供應鏈、產生證據並實現以患者為中心的AATD療法的商業化。

為了駕馭複雜且快速發展的抗胰蛋白酶缺乏症（AATD）生態系統，產業領導者應優先考慮一系列切實可行的策略，以平衡短期營運韌性和長期創新。首先，透過對多家地理位置分散的供應商進行資格認證，並在條件允許的情況下投資國內生產能力，實現血漿衍生材料和載體生產供應鏈的多元化，從而降低關稅和物流風險。其次，將可靠的真實世界資料收集和病患報告結果納入試驗設計和核准後註冊研究，以加速產生能夠消除支付方顧慮並加強報銷談判的臨床證據。

第三，透過開發適當的給藥途徑和製劑，例如院內啟動、居家持續治療或門診吸入維持治療，使產品開發與供應和分銷實際情況相符。第四，與契約製造、專科藥房和臨床研究中心建立跨學科合作，以確保生產的擴充性和高品質的患者支援。第五，積極與監管機構和衛生技術評估機構合作，確定可接受的終點指標和風險管理計劃，尤其針對新型基因療法。最後，投資於以患者為中心的項目，以減少依從性障礙並支持長期監測，尤其是在兒童和老年人群中，因為這些人群的安全性和耐受性考慮因素有所不同。透過協作實施這些建議，各機構可以維持藥物的可及性，最大限度地減少營運中斷，並增強新型治療方法的臨床提案。

本執行摘要清楚地描述了一種混合調查方法，該方法結合了初步訪談、文獻綜合和供應商營運評估，以得出可靠的實用結論。

本執行摘要的研究整合了多種調查方法，對α1-抗胰蛋白酶缺乏症的治療現狀進行了嚴謹而實用的分析。主要研究包括對臨床研究人員、專科藥劑師、生產經理和支付方代表進行結構化訪談，以收集有關臨床實踐、營運限制和醫保覆蓋範圍等方面的第一手觀點。次要研究包括對同行評審文獻、臨床試驗註冊庫、監管指導文件和上市公司披露資訊進行全面審查，以梳理科學進展、臨床試驗活動和監管預期。

供應鏈和製造方面的洞察來自供應商評估和公開的產能報告，而分銷管道分析則納入了藥房服務產品和居家照護項目模式的數據。在適當情況下，我們檢驗驗證了主要和次要來源，以檢驗趨勢並識別相互矛盾的訊號。透過跨職能審查和品質保證檢查，我們保持了分析的徵兆，確保結論反映出一致的證據。此調查方法的局限性包括臨床計畫推廣時間表的不確定性以及政策環境變化所帶來的不確定性。為了緩解這些局限性，我們強調風險調整後的情境和營運應對措施，而非精確的數值預測。

具有前瞻性的綜合願景，強調在研發、生產和支付方參與等環節開展協作策略，以將科學進步轉化為病患持續的用藥途徑。

生物製藥、基因創新和不斷演進的分銷模式的融合，標誌著α1-抗胰蛋白酶缺乏症治療的關鍵轉折點。科學進步正在創造實際的機會，使我們從症狀治療轉向更永續的治療方案，但要實現這一目標，需要製定一套涵蓋臨床開發、生產韌性和醫保支付方參與的綜合策略。透過將載體平台選擇與給藥方式相匹配，並將可靠的真實世界證據納入監管和報銷討論，相關人員可以減少推廣應用的障礙，並改善患者的治療效果。

展望未來，研發人員、契約製造、專科醫療機構和支付方之間的合作對於將科學進步轉化為廣泛的患者獲益至關重要。營運準備情況，尤其是在供應鏈多元化和定價策略方面，將決定哪些治療方法能夠實現永續的可及性。最終，以患者為中心，優先考慮安全性、長期監測和公平可及性的方法，不僅能夠推進臨床治療，還能為該治療領域的創新治療方法開闢永續的商業性道路。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用CRISPR技術進行新興基因編輯療法，在肺部達到α1-抗胰蛋白酶的持續表達
  • 吸入式重組AAT製劑的臨床進展，旨在提高患者依從性和治療效果
  • 整合遠端醫療平台，用於即時監測和個人化管理AAT缺乏症
  • 透過擴大新生兒篩檢計劃，促進α1-抗胰蛋白酶缺乏症的早期診斷和治療
  • 在歐洲法規環境變化與價格壓力下，生物相似藥AAT產品打入市場策略
  • 一種創新的基於奈米顆粒的遞送系統，可增強α-1抗胰蛋白酶療法的肺部標靶化
  • 長效AAT製劑的引入可減少輸血頻率並提高慢性治療的依從性
  • 擴大患者登記合作，以產生真實世界證據，支持對AAT療法進行健康技術評估。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療方法的α1-抗胰蛋白酶缺乏症治療市場

  • 替代療法
  • 基因治療
    • AAV載體
    • 慢病毒載體
  • 血漿輸注

9. 依分銷管道分類的α1-抗胰蛋白酶缺乏症治療市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

10. 依給藥方式分類的α1-抗胰蛋白酶缺乏症治療市場

  • 吸入
  • 靜脈注射

第11章 以最終用戶分類的α1-抗胰蛋白酶缺乏症治療市場

  • 居家醫療
  • 醫院
  • 專科診所

12. 依患者年齡層分類的α1-抗胰蛋白酶缺乏症治療市場

  • 成人
  • 老年人
  • 孩子們

13. 各地區α1-抗胰蛋白酶缺乏症治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 α1-抗胰蛋白酶缺乏症治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國α1-抗胰蛋白酶缺乏症治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Grifols SA
    • CSL Behring GmbH
    • Takeda Pharmaceutical Company Limited
    • Kamada Pharmaceuticals
    • Vertex Pharmaceuticals
Product Code: MRR-C002B1C99847

The Alpha 1 Antitrypsin Deficiency Treatment Market is projected to grow by USD 6.79 billion at a CAGR of 9.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.26 billion
Estimated Year [2025] USD 3.57 billion
Forecast Year [2032] USD 6.79 billion
CAGR (%) 9.62%

A clear and compelling overview of the evolving therapeutic paradigm for alpha-1 antitrypsin deficiency that frames scientific advances and patient access challenges

Alpha-1 antitrypsin deficiency remains a clinically significant, genetically driven disorder that disproportionately affects pulmonary and hepatic function, prompting an evolving therapeutic landscape that blends established biologics with next-generation genetic interventions. Over the past decade, clinical practice has relied on augmentation approaches and plasma-derived therapies to stabilize patients with lung-dominant disease, while a surge of translational research has propelled gene-based strategies toward the clinic. Consequently, stakeholders across development, manufacturing, and care delivery are recalibrating priorities to reconcile long-term clinical promise with near-term access challenges.

As this executive summary outlines, the field is characterized by a diversified set of therapeutic modalities and delivery paradigms. Traditional augmentation therapy and plasma infusion remain core treatment options for many patients, while gene therapy platforms-distinguished by adeno-associated viral vectors and lentiviral vectors-are advancing as potentially curative alternatives. Parallel shifts in distribution-from hospital pharmacies to online and retail channels-and delivery modes such as inhalation and intravenous administration are reshaping how therapies reach patients. Patient age heterogeneity, including adult, geriatric, and pediatric populations, further complicates clinical pathways and reimbursement approaches. Taken together, these dynamics demand coordinated strategy across research, supply chain, and commercial execution to translate scientific advances into tangible patient benefit.

How converging scientific advances, delivery innovations, and distribution shifts are reshaping clinical development and commercial execution for AATD therapies

The treatment landscape for alpha-1 antitrypsin deficiency is undergoing transformative shifts driven by scientific, regulatory, and commercial inflection points that collectively redefine development priorities. Breakthroughs in vector biology and gene-editing platforms have accelerated translational activity, increasing the frequency of early-phase studies that explore both AAV vector-based and lentiviral vector-based approaches. At the same time, improvements in vector manufacturing, purification, and capsid engineering are narrowing the gap between laboratory promise and scalable clinical supply, which in turn influences sponsor planning for pivotal programs.

Concurrently, delivery-mode innovation is reshaping clinical design and patient experience. Inhalation strategies aimed at direct pulmonary delivery are gaining traction for lung-centric disease control, while intravenous routes continue to be optimized for systemic exposure and gene delivery. Distribution channels are adapting as well, with hospital pharmacy settings retaining a central role for complex infusions and specialty procedures, while online and retail pharmacies scale to support maintenance therapies and chronic care logistics. These technical and logistical changes intersect with payer expectations and regulatory pathways, prompting developers to invest in robust real-world evidence generation and long-term safety monitoring. As a result, partnerships between biotech innovators, contract development organizations, and specialty care networks are becoming essential for moving candidates from bench to bedside at pace.

Strategic implications of recent United States tariff policy changes on biologics supply chains, procurement dynamics, and patient access pathways in 2025

Policy changes in trade and tariff regimes have real and rapidly materializing implications for the pharmaceutical and biologics ecosystem, and the cumulative impact of United States tariffs announced in 2025 warrants strategic attention across supply chain, procurement, and pricing channels. Tariffs affecting imported raw materials and manufacturing components can increase direct production costs for plasma-derived products and biologic vector manufacturing, which rely on specialized reagents and equipment often sourced internationally. These cost pressures ripple through contract manufacturing relationships and may necessitate renegotiation of supplier terms or strategic reallocation of manufacturing volumes to domestic facilities.

Beyond direct cost effects, tariffs can introduce complexity into supply chain planning by reducing inventory flexibility and increasing lead times for critical inputs, thereby heightening operational risk for programs reliant on steady plasma supplies or on-time vector production. Procurement teams within hospital pharmacies and specialty clinics may experience tighter margins, potentially prompting shifts in purchasing patterns or contract structures. In response, sponsorship organizations may accelerate localization of key manufacturing steps, pursue long-term supply agreements, or qualify alternative suppliers to mitigate exposure. Importantly, regulatory considerations and payer negotiations will influence how any incremental costs are ultimately distributed across payers, providers, and patients, so cross-functional mitigation strategies that include evidence generation and pricing models are essential to preserve patient access.

Deep segmentation insights describing how therapy class, distribution pathways, delivery modes, end-use settings, and patient age groups define strategic priorities and operational trade-offs

A segmented view of the alpha-1 antitrypsin deficiency therapeutic landscape highlights distinct commercial and clinical vectors that stakeholders must address to optimize development and deployment. Considering therapy class, augmentation therapy and plasma infusion continue to form the backbone of current management for many patients, with operational emphasis on plasma collection networks, cold-chain logistics, and infusion infrastructure. Gene therapy occupies a different risk-reward profile; within this class, AAV vector approaches are favored for in vivo gene delivery targeting the liver or lungs, whereas lentiviral vector strategies are typically explored in ex vivo hematopoietic paradigms or for certain systemic delivery goals. Each vector type carries unique manufacturing, immunogenicity, and regulatory considerations that shape clinical trial design and long-term safety monitoring.

Distribution channel dynamics exert material influence over patient access and adherence. Hospital pharmacies remain critical for complex, administration-intensive therapies and for initial gene therapy dosing, while online pharmacies are emerging as convenient conduits for chronic treatments and patient home delivery programs. Retail pharmacies provide neighborhood-level access and often support continuity of care for maintenance regimens. Delivery mode selection further segments patient experience: inhalation therapies offer targeted pulmonary deposition and potentially greater convenience for ambulatory patients, while intravenous delivery supports systemic exposure and controlled dosing in clinical settings. End-user distinctions matter as well; homecare models enable patients to receive chronic infusions outside institutional settings, hospitals serve as centers for acute management and complex procedures, and specialty clinics concentrate expertise for gene therapy administration and long-term monitoring. Finally, patient age group creates clinical variability that influences therapeutic selection, dosing strategies, and safety surveillance: pediatric populations require pediatric-specific formulations and developmental safety data, adults typically represent the largest treated cohort, and geriatrics bring comorbidity and polypharmacy considerations that affect tolerability and outcomes.

How distinct regional regulatory environments, clinical infrastructure, and supply chain capabilities shape development pathways and patient access across global markets

Regional dynamics materially influence clinical development, reimbursement strategy, and supply chain resilience for alpha-1 antitrypsin deficiency programs. In the Americas, concentrated research activity and extensive clinical trial infrastructure, alongside established plasma collection systems, create an environment conducive to advanced therapeutic development. Regulatory pathways remain a central consideration, with agencies requiring robust safety and long-term follow-up data that inform trial endpoints and post-approval obligations. Commercial stakeholders in this region must also navigate payer expectations and complex hospital procurement processes to ensure therapy uptake.

Europe, the Middle East & Africa present a heterogeneous regulatory and access landscape where centralized and national-level frameworks intersect. Several European markets provide strong orphan drug incentives and expedited review mechanisms, yet access can vary substantially by country due to differing reimbursement thresholds and health technology assessment requirements. In parts of the Middle East and Africa, constrained plasma infrastructure and limited specialty care networks can complicate implementation of advanced therapies, underscoring the importance of targeted capacity-building efforts.

Asia-Pacific is characterized by rapid growth in clinical research activity, increasing local manufacturing capabilities, and evolving regulatory harmonization efforts that aim to accelerate clinical development timelines. Several countries in this region are investing in biomanufacturing and vector production capacity, which can support regional supply diversification. However, patient access and pricing dynamics differ across markets, requiring nuanced commercialization strategies that reflect local payer systems, distribution ecosystems, and medical practice patterns. Across all regions, cross-border supply chains, tariff exposure, and logistics contingencies remain central to ensuring consistent product availability and sustained patient care.

Insights into how strategic partnerships, manufacturing investments, and evidence-generation programs among industry players are accelerating clinical translation and commercialization

Company- and ecosystem-level behaviors are shaping the pace at which innovative AATD therapies move from concept to clinic and ultimately into routine care. A diverse mix of small biotech innovators, established plasma therapeutics firms, contract development and manufacturing organizations, and specialty pharmacy networks contribute complementary capabilities across discovery, vector production, and patient support. Strategic alliances and licensing agreements are increasingly common as developers seek to combine scientific expertise with scale manufacturing competence and established distribution networks.

Commercial players are prioritizing capability investments in vector manufacturing, cold-chain logistics, and patient support services to address the operational complexities of both gene therapy and plasma-derived products. Contract manufacturers that can demonstrate consistent yields and regulatory-compliant quality systems become strategic partners for sponsors aiming to derisk pivotal programs. Meanwhile, specialty pharmacies and home infusion providers are enhancing clinical support and monitoring programs to optimize adherence and safety. On the business side, companies are also focusing on evidence generation strategies that align clinical outcomes with payer requirements, emphasizing real-world effectiveness, quality-of-life measures, and long-term safety data to support coverage and reimbursement discussions. Collectively, these company-level choices underscore a shift toward integrated, cross-functional approaches that blend clinical excellence with commercial pragmatism.

Practical and prioritized strategic steps for sponsors and partners to strengthen supply chains, evidence generation, and patient-centric commercialization for AATD therapies

To navigate the complex and rapidly evolving AATD ecosystem, industry leaders should prioritize a set of actionable strategies that balance near-term operational resilience with long-term innovation. First, diversify supply chains for plasma-derived inputs and vector manufacturing by qualifying multiple suppliers across geographies and by investing in domestic manufacturing capacity where feasible to mitigate tariff and logistics exposure. Second, accelerate clinical evidence generation that addresses payer concerns by incorporating robust real-world data collection and patient-reported outcomes into trial designs and post-approval registries, thereby strengthening reimbursement dialogues.

Third, align product development with delivery and distribution realities by designing formulations and administration pathways that suit hospital-based initiation, homecare continuation, or inhaled outpatient maintenance as appropriate. Fourth, build cross-sector partnerships with contract manufacturing organizations, specialty pharmacies, and clinical centers of excellence to ensure scalable production and high-quality patient support. Fifth, engage proactively with regulators and health technology assessment bodies to define acceptable endpoints and risk management plans, especially for novel gene therapies. Finally, invest in patient-centric programs that reduce adherence barriers and support long-term monitoring, particularly for pediatric and geriatric populations where safety and tolerability considerations differ. These recommendations, implemented in concert, will help organizations preserve access, limit operational disruption, and enhance the clinical value proposition of new therapies.

A transparent description of the mixed-methods research approach combining primary interviews, literature synthesis, and operational vendor assessment to ensure robust and actionable conclusions

The research underpinning this executive summary integrates multiple lines of inquiry to produce a rigorous and actionable synthesis of the alpha-1 antitrypsin deficiency treatment landscape. Primary research included structured interviews with clinical investigators, specialty pharmacists, manufacturing leaders, and payer representatives to capture frontline perspectives on clinical practice, operational constraints, and coverage considerations. Secondary research encompassed a comprehensive review of peer-reviewed literature, clinical trial registries, regulatory guidance documents, and public company disclosures to map scientific progress, trial activity, and regulatory expectations.

Supply chain and manufacturing insights were derived from vendor assessments and publicly available manufacturing capacity reports, while distribution-channel analysis incorporated data on pharmacy service offerings and homecare program models. Where appropriate, triangulation was applied across primary and secondary sources to validate trends and to identify divergent signals. Analytical rigor was maintained through cross-functional review and quality assurance checks to ensure that conclusions reflect consistent evidence. Limitations of the methodology include variability in publicly reported timelines for clinical programs and the inherent uncertainty associated with evolving policy environments, which we mitigated by emphasizing risk-adjusted scenarios and operational contingencies rather than precise numerical projections.

A forward-looking synthesis emphasizing coordinated strategies across development, manufacturing, and payer engagement to translate scientific progress into sustained patient access

The convergence of biologic therapies, gene-based innovation, and evolving distribution models presents a pivotal moment for the management of alpha-1 antitrypsin deficiency. Scientific advances create tangible opportunities to move beyond symptomatic control toward more durable therapeutic outcomes, yet realizing that potential requires coherent strategies that span clinical development, manufacturing resilience, and payer engagement. By aligning vector platform choices with delivery modalities and by integrating robust real-world evidence into regulatory and reimbursement conversations, stakeholders can reduce barriers to adoption and improve patient outcomes.

Moving forward, collaboration among developers, contract manufacturers, specialty care providers, and payers will be essential to translate scientific progress into broad patient benefit. Operational preparedness-particularly with respect to supply chain diversification and pricing strategies-will determine which therapies achieve sustainable access. Ultimately, a patient-centered approach that prioritizes safety, long-term monitoring, and equitable access will not only advance clinical care but also create durable commercial pathways for innovative treatments in this therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging gene editing therapies leveraging CRISPR technology for durable alpha 1 antitrypsin expression in the lung
  • 5.2. Clinical advancement of recombinant AAT inhalation formulations to improve patient compliance and outcomes
  • 5.3. Integration of telemedicine platforms for real-time monitoring and personalized management of AAT deficiency
  • 5.4. Expansion of newborn screening initiatives to facilitate early diagnosis and treatment of alpha 1 antitrypsin deficiency
  • 5.5. Market entry strategies for biosimilar AAT products in Europe amid evolving regulatory and pricing pressures
  • 5.6. Innovative nanoparticle-based delivery systems enhancing pulmonary targeting of alpha 1 antitrypsin therapies
  • 5.7. Adoption of long-acting AAT formulations reducing infusion frequency and improving adherence in chronic therapy
  • 5.8. Growing patient registry collaborations generating real-world evidence to support health technology assessments for AAT treatments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alpha 1 Antitrypsin Deficiency Treatment Market, by Therapy Class

  • 8.1. Augmentation Therapy
  • 8.2. Gene Therapy
    • 8.2.1. AAV Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Plasma Infusion

9. Alpha 1 Antitrypsin Deficiency Treatment Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Alpha 1 Antitrypsin Deficiency Treatment Market, by Delivery Mode

  • 10.1. Inhalation
  • 10.2. Intravenous

11. Alpha 1 Antitrypsin Deficiency Treatment Market, by End User

  • 11.1. Homecare
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Alpha 1 Antitrypsin Deficiency Treatment Market, by Patient Age Group

  • 12.1. Adults
  • 12.2. Geriatrics
  • 12.3. Pediatrics

13. Alpha 1 Antitrypsin Deficiency Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Alpha 1 Antitrypsin Deficiency Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Alpha 1 Antitrypsin Deficiency Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Grifols S.A.
    • 16.3.2. CSL Behring GmbH
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Kamada Pharmaceuticals
    • 16.3.5. Vertex Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AUGMENTATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY AAV VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PLASMA INFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 134. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 148. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 203. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2018-2024 (USD MILLION)
  • TABLE 274. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET SIZE, BY THERAPY CLASS, 2025-2032 (USD MILLION)
  • TABLE 275. BRICS ALPHA 1 ANTITRYPSIN DEFICIENCY T